The ongoing research on pioneering drug candidates for the overactive bladder(OAB) aimed to overcome the limitations of currently licensed pharmacotherapies, such as antimuscarinics, β3-adrenergic agents, and botulin...The ongoing research on pioneering drug candidates for the overactive bladder(OAB) aimed to overcome the limitations of currently licensed pharmacotherapies, such as antimuscarinics, β3-adrenergic agents, and botulinum neurotoxin, has been reviewed performing a systematic literature review and web search. The review covers the exploratory agents alternative to available medications for OAB and that may ultimately prove to be therapeutically useful in the future management of OAB patients based on preclinical and early clinical data. It emerges that many alternative pharmacological strategies have been discovered or are under investigation in disease-oriented studies. Several potential therapeutics are known for years but still find obstacles to pass the clinical stages of development, while other completely novel compounds, targeting new pharmacological targets, have been recently discovered and show potential to translate into clinical therapeutic agents for idiopathic and neurogenic OAB syndrome. The global scenario of investigational drugs for OAB gives promise for the development of innovative therapeutics that may ultimately prove effective as first, combined or second-line treatments within a realistic timescale of ten years.展开更多
目的探讨膀胱癌合并良性前列腺增生的同期经尿道微创治疗。方法合并良性前列腺增生可经尿道电切治疗的膀胱癌患者56例同期行经尿道前列腺切除、部分切除或切开。结果随访6～84个月,5例复发,无尿道及前列腺窝转移。结论合并良性前列腺增...目的探讨膀胱癌合并良性前列腺增生的同期经尿道微创治疗。方法合并良性前列腺增生可经尿道电切治疗的膀胱癌患者56例同期行经尿道前列腺切除、部分切除或切开。结果随访6～84个月,5例复发,无尿道及前列腺窝转移。结论合并良性前列腺增生可予经尿道膀胱肿瘤切除术(transurethral resection of bladder tumor,TURBT)的非浸润性膀胱肿瘤或膀胱尿路上皮癌患者适应行同期微创治疗。展开更多
文摘The ongoing research on pioneering drug candidates for the overactive bladder(OAB) aimed to overcome the limitations of currently licensed pharmacotherapies, such as antimuscarinics, β3-adrenergic agents, and botulinum neurotoxin, has been reviewed performing a systematic literature review and web search. The review covers the exploratory agents alternative to available medications for OAB and that may ultimately prove to be therapeutically useful in the future management of OAB patients based on preclinical and early clinical data. It emerges that many alternative pharmacological strategies have been discovered or are under investigation in disease-oriented studies. Several potential therapeutics are known for years but still find obstacles to pass the clinical stages of development, while other completely novel compounds, targeting new pharmacological targets, have been recently discovered and show potential to translate into clinical therapeutic agents for idiopathic and neurogenic OAB syndrome. The global scenario of investigational drugs for OAB gives promise for the development of innovative therapeutics that may ultimately prove effective as first, combined or second-line treatments within a realistic timescale of ten years.
文摘目的探讨膀胱癌合并良性前列腺增生的同期经尿道微创治疗。方法合并良性前列腺增生可经尿道电切治疗的膀胱癌患者56例同期行经尿道前列腺切除、部分切除或切开。结果随访6～84个月,5例复发,无尿道及前列腺窝转移。结论合并良性前列腺增生可予经尿道膀胱肿瘤切除术(transurethral resection of bladder tumor,TURBT)的非浸润性膀胱肿瘤或膀胱尿路上皮癌患者适应行同期微创治疗。
